Want to see SE:QLIFE full AI Analyst Report?
QLIFE Stock Chart & Stats
kr3.01
-kr0.24(-7.59%)
At close: 4:00 PM EST
kr3.01
-kr0.24(-7.59%)
Day’s Range― - ―
52-Week Rangekr0.85 - kr3.77
Previous CloseN/A
Volume24.68K
Average Volume (3M)85.60K
Market Cap
kr30.14M
Enterprise Valuekr45.84M
Total Cash (Recent Filing)kr4.36M
Total Debt (Recent Filing)kr8.35M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.89
Shares Outstanding28,874,178
10 Day Avg. Volume129,413
30 Day Avg. Volume85,598
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-4.74
Price to Sales (P/S)109.73
P/FCF Ratio-1.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-126.16
Revenue Forecast (FY)kr116.00M
Bulls Say, Bears Say
Bulls Say
Revenue AccelerationThe sharp increase in trailing revenue indicates growing commercial activity and potential customer adoption of Qlife’s diagnostic offering. Although the base remains small, continued expansion could improve operating leverage and support a more scalable business model over the next several quarters.
Equity StabilizationThe return to positive equity represents a meaningful improvement in Qlife’s capital structure compared with recent years. This provides a stronger financial foundation for commercialization and may reduce immediate balance-sheet pressure, even though leverage and funding needs remain significant.
Recurring Consumables ModelA platform supported by single-use cartridges or reagents can create repeat revenue as instruments are deployed and tests are performed. This installed-base model may improve revenue visibility and customer retention, while increasing the long-term value of successful platform adoption.
Bears Say
Severe UnprofitabilityExtremely negative margins show that Qlife has not yet reached an economically sustainable level of operations. Persistent losses suggest revenue growth is currently insufficient to cover the cost base, limiting internal funding capacity and making successful scaling essential to future profitability.
Persistent Cash BurnMaterially negative operating and free cash flow means Qlife is not self-funding its activities through current operations. Continued cash consumption can restrict investment flexibility and increase dependence on external capital, particularly if commercialization takes longer or requires additional spending.
High Leverage And Funding RiskDebt remains high relative to the company’s equity base, limiting financial flexibility while losses continue. The prior period of negative equity also indicates structural funding pressure, raising the possibility that further financing or dilution could be needed to sustain operations and growth.
QLIFE FAQ
What was Qlife Holding AB’s price range in the past 12 months?
Qlife Holding AB lowest stock price was kr0.85 and its highest was kr3.77 in the past 12 months.
What is Qlife Holding AB’s market cap?
Qlife Holding AB’s market cap is kr30.14M.
When is Qlife Holding AB’s upcoming earnings report date?
Qlife Holding AB’s upcoming earnings report date is Nov 11, 2026 which is in 15 days.
How were Qlife Holding AB’s earnings last quarter?
Qlife Holding AB released its earnings results on Aug 26, 2026. The company reported -kr0.238 earnings per share for the quarter.
Is Qlife Holding AB overvalued?
According to Wall Street analysts Qlife Holding AB’s price is currently Overvalued.
Does Qlife Holding AB pay dividends?
Qlife Holding AB does not currently pay dividends.
What is Qlife Holding AB’s EPS estimate?
Qlife Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Qlife Holding AB have?
Qlife Holding AB has 28,874,178 shares outstanding.
What happened to Qlife Holding AB’s price movement after its last earnings report?
Qlife Holding AB reported an EPS of -kr0.238 in its last earnings report. Following the earnings report the stock price went down -5.869%.
Which hedge fund is a major shareholder of Qlife Holding AB?
Currently, no hedge funds are holding shares in SE:QLIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Qlife Holding AB
Operating as a medical technology firm, Qlife Holding AB (publ) specializes in the production and distribution of in-vitro diagnostic instruments and their associated chemical reagents. Their flagship offering is the Egoo.Health Platform, a comprehensive system comprising a measuring device, single-use test capsules, and integrated software. This innovative platform facilitates the detection of various biomarkers or viral agents, with each capsule tailored for a distinct diagnostic purpose. The range of supported biomarkers encompasses C-reactive protein for home-based monitoring, Phenylalanine (PHE) vital for managing Phenylketonuria (PKU) in patients, and a multiplex test designed to identify Sars-CoV-2 and Influenza, aiding in the detection of viral and bacterial infections. Established in 2019, Qlife's operations are headquartered in Helsingborg, Sweden.